Navigation Links
Abbott's Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
Date:3/31/2008

lipid problems."

Treatment guidelines endorsed by the National Cholesterol Education Panel (NCEP), the ACC and the American Heart Association have called for more aggressive management of lipids, including a lower LDL goal for many patients, as well as more aggressive management of HDL and triglycerides.

About the TriLipix Clinical Program

The two studies being presented at the ACC conference are part of a broad clinical program to evaluate the efficacy and safety of TriLipix combined with statins. The efficacy and safety of TriLipix in combination with the three most commonly prescribed statins -- rosuvastatin, atorvastatin and simvastatin -- were evaluated in three randomized, multi-center, double-blind, controlled, 12-week Phase III studies, totaling 2,698 patients with mixed dyslipidemia. Patients included in the studies had multiple lipid problems, with an LDL greater than 130 mg/dL, triglycerides greater than 150 mg/dL and HDL less than 40 mg/dL for men and less than 50 mg/dL for women.

These studies, along with a 52-week long-term efficacy and safety open-label extension study of 1,911 patients, represent the largest program to date examining the efficacy and safety of a fibrate in combination with statins. More than 2,200 patients were treated with TriLipix in combination with statins across the four studies.

In the atorvastatin and simvastatin studies, presented at the ACC conference, 613 and 657 patients, respectively, were randomized to receive either TriLipix (135mg) combined with either 20mg or 40mg of the corresponding statin, TriLipix monotherapy (135mg) or statin monotherapy (20mg, 40mg or 80mg). The 80mg statin monotherapy arm was included in the study to assess safety and adverse events, but was not included in the statistical analysis.

The primary efficacy comparisons were mean percent change in HDL and triglycerides in the combination versus a statin alone, and mean percent change in LDL in the combinati
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
2. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
3. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
6. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
7. Metabolex Initiates Phase 1 Trial of MBX-2982
8. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
9. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
10. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
11. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... N.J. , July 24, 2014 /PRNewswire/ ... CTSH ) today announced that it has ... , a non-profit organization with membership representation ... a first-of-its-kind, subscription-based platform that will transform ... companies on clinical trials. TransCelerate BioPharma Inc. ...
(Date:7/23/2014)... 2014  Varian Medical Systems (NYSE: VAR ... diluted share in the third quarter of fiscal year ... per diluted share due to an approximately $8 million ... equity investment in Augmenix, a privately-held company developing minimally ... million for the third quarter of fiscal year 2014, ...
(Date:7/23/2014)... DUBLIN , July 23, 2014 ... "Diagnostic Electrocardiograph (ECG) Market by Product, End-user & ... report to their offering. ... market is segmented into three major segments, namely, holter ... overall market was valued at $3,683 million in 2013 ...
Breaking Medicine Technology:TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 2TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 3TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 4TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 3Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 4Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 6Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 7Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 8Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 9Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 10Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3
... Cayenne Medical, Inc., a private sports medicine device ... that effective immediately, David B. Springer will succeed James ... transitioned to Executive Chairman due to health reasons. ... President and CEO since the company,s inception in 2005, ...
... ACCESS PHARMACEUTICALS, INC. ... a biopharmaceutical company leveraging its proprietary drug-delivery platforms to ... and diabetes, reported it has been receiving ... MuGard for patients undergoing radiation and chemotherapy for various ...
Cached Medicine Technology:Cayenne Medical, Inc. Appoints David B. Springer President & CEO 2Cayenne Medical, Inc. Appoints David B. Springer President & CEO 3Access Pharmaceuticals Receives Early MuGard Prescriber Anecdotal Feedback Validating Larger Target Market Potential 2Access Pharmaceuticals Receives Early MuGard Prescriber Anecdotal Feedback Validating Larger Target Market Potential 3Access Pharmaceuticals Receives Early MuGard Prescriber Anecdotal Feedback Validating Larger Target Market Potential 4
(Date:7/24/2014)... Professional Healthcare at Home, an affiliate of ... a nurse with the company’s Pleasant Hill, CA, home health ... the 2014 Home Care & Hospice Nurse of the Year ... Hospice (NAHC). , Annually, NAHC promotes a nationwide recognition ... help choose a top home care and hospice nurse from ...
(Date:7/24/2014)... Imbue Partners is pleased ... (WOSB) by the National Women Business Owners Corporation ( ... party certifier. , Located near Boston, MA, Imbue ... to drive growth through strategic planning, organizational competencies, and ... activating options through teams, tools, and technologies for all ...
(Date:7/24/2014)... Colleen’s Dream Foundation, in partnership with Fidelity ... Medicine to fund ovarian cancer research, according to Colleen’s ... this is the second year in a row Colleen's ... Hopkins Medicine. , “One of the main goals of ... investigators at some of the top research hospitals and ...
(Date:7/23/2014)... Jose, CA (PRWEB) July 23, 2014 ... for health and beauty products do not include various ... company is now revealing skin tightening cream discounts inside ... . , The guide is now available to offer ... to find recently released products available for sale. Although ...
(Date:7/23/2014)... Men and women who are married ... insurance based on national averages. The Quotes Pros company ... to its comprehensive tool this year to help married ... , Providers that are now underwriting plans on a ... one or two clicks. The intelligent platform used to ...
Breaking Medicine News(10 mins):Health News:Professional Healthcare at Home’s Karen Schulkin Named Top 10 Finalist Representing California for 2014 Home Care & Hospice Nurse of the Year 2Health News:Professional Healthcare at Home’s Karen Schulkin Named Top 10 Finalist Representing California for 2014 Home Care & Hospice Nurse of the Year 3Health News:Imbue Partners Certified as Woman-Owned Small Business 2Health News:Colleen’s Dream Foundation Donates $10,000 to Johns Hopkins Medicine for Ovarian Cancer Research 2Health News:Colleen’s Dream Foundation Donates $10,000 to Johns Hopkins Medicine for Ovarian Cancer Research 3Health News:Skin Tightening Cream Discounts Revealed in New Cost Saving Guide at Consumer Portal 2Health News:Cheap Life Insurance Rates for Married Couples Added to Search System at Insurer Portal Online 2
... have reported that use of narcotics for chronic pain ... //ask for increasing the dose. On the other hand, ... lead to constant increase in the dosage with serious ... pain medications like morphine, methadone and oxycodone. Opioid drugs ...
... Korean scientists have been able to clone human embryos for ... with diseases or injury. The newly created stem cell lines ... systems. ,. ,This research have provided new insight into ... on them as a treatemnt. This is for the first ...
... that colonoscopy may be the favorable method to screen ... colorectal cancer, flexible sigmoidoscopy is used to detect colorectal ... with dysplasia, or cancer. Researchers had used colonoscopy to ... for women who were referred for colon-cancer screenings. ,Of ...
... infection of the lungs, says a study published in the ... of age between 2 to 49 years for a period ... pneumococcal disease, 10 persons of the same population were chosen ... of diagnosis of asthma by the emergency room, or the ...
... of colon cancer after undergoing surgery can reduce the risk ... which was presented at the annual meeting of American Society ... by about 50% for the patients who took regular aspirin ... cancer. ,Colon and rectum together form the colorectal area. ...
... Attention Deficit Hyperactivity Syndrome (ADHD) may now to treated ... interventions like applying deep pressure or putting them through ... is a condition that affects nearly 3 to 5 ... Children with ADHD are known to be impulsive, inattentive ...
Cached Medicine News:
... Random Dot Stereo Depth Perception for ... of arc) and Fine Depth,Perception. , ... (800 to 40 sec of arc), ... to 100 sec of arc), 1 ...
Our high quality therapeutic drug monitoring reagents, calibrators and controls are available for most chemistry analyzers. Reproducible and accurate results for your laboratory needs....
The Emit 2000 Phenytoin Assay is a homogeneous enzyme immunoassay for use in the quantitative analysis of phenytoin in human serum or plasma. Kits are conveniently packaged in Olympus Reagent Cartrid...
... Digoxin Assay is a homogeneous ... in the quantitative analysis of ... plasma. Kits are packaged specifically ... COBAS MIRA, COBAS MIRA S, ...
Medicine Products: